J7
J7Z.F Jazz Pharmaceuticals plc
- Market cap
- EUR 14.0B
- P/E
- 75.1x
- P/B
- 3.83x
- ROE
- 0.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is J7Z.F undervalued?
Graham numberThe Graham number of Jazz Pharmaceuticals plc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jazz Pharmaceuticals plc fundamental analysis
No fundamental analysis for Jazz Pharmaceuticals plc yet.
Jazz Pharmaceuticals plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymp…
Full company profileJazz Pharmaceuticals plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jazz Pharmaceuticals plc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.49B | 1.62B | 1.89B | 2.16B | 2.36B | 3.09B | 3.66B | 3.83B | 4.07B | 4.27B | 4.69B |
| Gross Profit | 1.38B | 1.51B | 1.77B | 2.03B | 2.21B | 2.65B | 3.12B | 3.40B | 3.62B | 3.76B | 4.21B |
| Operating Income | 615M | 614M | 658M | 642M | 765M | 170M | 512M | 598M | 727M | 518M | 1.17B |
| EBITDA | - | 684M | 823M | 897M | 653M | 718M | 515M | 1.23B | 1.37B | 263M | 951M |
| Net Income | 397M | 488M | 447M | 523M | 239M | -330M | -224M | 415M | 560M | -356M | 3.33M |
| EPS | - | 8.14 | 7.78 | 9.32 | 4.25 | -5.37 | -3.54 | 6.66 | 9.24 | -5.80 | 0.05 |
| Balance Sheet | |||||||||||
| Total Assets | 4.80B | 5.12B | 5.20B | 5.54B | 6.54B | 12.3B | 10.8B | 11.4B | 12.0B | 11.7B | 12.0B |
| Total Liabilities | 2.92B | 2.41B | 2.45B | 2.43B | 2.88B | 8.33B | 7.75B | 7.66B | 7.92B | 7.34B | 7.81B |
| Shareholders' Equity | 1.88B | 2.71B | 2.76B | 3.11B | 3.66B | 3.97B | 3.09B | 3.74B | 4.09B | 4.32B | 4.19B |
| Cash & Short-term Investments | 366M | 386M | 310M | 637M | 1.06B | 591M | 881M | 1.51B | 2.41B | 1.39B | 2.04B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 592M | 693M | 799M | 776M | 900M | 779M | 1.27B | 1.09B | 1.40B | 1.36B | 1.77B |
| Capital Expenditure | 182M | 29.0M | 20.4M | 40.1M | 15.0M | 27.6M | 29.0M | 43.0M | 48.1M | 210M | 278M |
| Free Cash Flow | - | 579M | 667M | 594M | 520M | 733M | 1.27B | 1.05B | 1.35B | 1.15B | 1.50B |
| Ratios | |||||||||||
| ROE | 21.1% | 18.0% | 16.2% | 16.8% | 6.5% | -8.3% | -7.3% | 11.1% | 13.7% | -8.2% | 0.1% |
| ROA | 8.3% | 9.5% | 8.6% | 9.4% | 3.7% | -2.7% | -2.1% | 3.6% | 4.7% | -3.1% | 0.0% |
| Net Profit Margin | 26.7% | 30.1% | 23.6% | 24.2% | 10.1% | -10.7% | -6.1% | 10.8% | 13.8% | -8.3% | 0.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Jazz Pharmaceuticals plc dividends
Jazz Pharmaceuticals plc has not paid dividends in the last 9 fiscal years.
Who owns Jazz Pharmaceuticals plc
- Insiders 2.95%
- Institutions 97.05%
- Public & others 0.00%
- Shares outstanding 64.2M
- Free float 62.3M
Jazz Pharmaceuticals plc company profile
- Company name
- Jazz Pharmaceuticals plc
- Ticker
- J7Z.F
- ISIN
- IE00B4Q5ZN47
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,890
- Fiscal year end
- December
- Address
- Waterloo Exchange, Dublin, Ireland, D04 E5W7
- Phone
- 353 1 634 7800
- Website
- jazzpharma.com
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Jazz Pharmaceuticals plc management
10- Mr. Bruce C. CozaddCo-Founder & Chairman · born 1964
- Ms. Renee D. GalaPresident, CEO & Director · born 1972
- Mr. Philip L. JohnsonExecutive VP & CFO · born 1964
- Ms. Neena M. Patil J.D.Executive VP & Chief Legal Officer · born 1975
- Dr. Robert Iannone M.D.Executive VP, Chief Medical Officer and Global Head of Research & Development · born 1967
- Ms. Samantha PearceExecutive VP & Chief Commercial Officer · born 1966
- Ms. Patricia CarrSenior VP & Chief Accounting Officer · born 1971
- Mr. John D. BluthHead of Investor Relations · born 1973
- Ms. Heidi MannaExecutive VP & Chief People Officer · born 1971
- Dr. Jed Black M.D.Senior Vice President of Sleep & CNS Medicine